Here are five things to know:
1. Three brokers rated the company a “Buy” and one rated a “Sell,” bringing the consensus to “Buy”
2. The company’s average 12-month price among covering brokers is $29.33 in the last year.
3. Piper Jaffray analysts reiterated an “overweight” rating and set a price target of $29 in a note on Friday.
4. Zacks analysts downgraded K2M shares at the end of May from “hold” to “sell.”
5. The company traded up today, hitting $24.74 and has a market cap of $981.06 million.
More articles on orthopedic devices:
BioMedical Enterprises launches nitinol bone fixation implant
DePuy Orthopaedics issues Class 2 recall for femoral implants
Boston Scientific launches Precision Novi SCS in Europe
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
